Fiserv earnings missed by $0.61, revenue fell short of estimates
Investing.com - Bernstein is previewing upcoming earnings for several biotech companies, expecting Alnylam Pharmaceuticals (NASDAQ:ALNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) to deliver healthy beats against consensus estimates. The biotech sector continues to show resilience, with companies like BioMarin showing strong fundamentals according to InvestingPro data.
According to Bernstein’s preview, Alnylam could see the most earnings volatility with potential for high single-digit percentage stock movement. The firm projects $650 million in Amvuttra revenues, approximately 4% above consensus estimates, and forecasts a 150% earnings per share beat due to what it describes as consensus mismodeling of collaboration revenues.
For Regeneron, Bernstein anticipates topline and EPS beats of 2% and 8% respectively, driven by strong Dupixent performance offset by softness in the Eylea franchise. The firm expects Vertex Pharmaceuticals (NASDAQ:VRTX) results to be roughly in line with consensus, projecting topline revenues of $3.08 billion and EPS of $4.64.
Bernstein models a 1% miss on both top and bottom lines for Biogen (NASDAQ:BIIB), with revenues of $2.32 billion and EPS of $3.87. For BioMarin Pharmaceutical (NASDAQ:BMRN), the firm expects a 1% beat on topline but a significant EPS miss that it attributes to consensus not fully reflecting the Inozyme transaction. InvestingPro data shows BMRN maintains robust financials with a perfect Piotroski Score of 9 and healthy revenue growth of 18.4% over the last twelve months. The stock currently appears undervalued according to InvestingPro’s Fair Value analysis.
Ionis Pharmaceuticals (NASDAQ:IONS) estimates are roughly in line with consensus across all metrics, including Trnygolza sales of $24 million, with Bernstein highlighting the upcoming American Heart Association presentation of olezarsen data on November 8 as the most important catalyst. For deeper insights into these biotech companies and access to comprehensive financial analysis, including 10+ additional ProTips and detailed Fair Value calculations, visit InvestingPro.
In other recent news, BioMarin Pharmaceutical Inc. has reported an anticipated in-process research and development (IPR&D) charge of approximately $221 million, stemming from its acquisition of Inozyme Pharma, Inc. This charge is expected to affect both GAAP and Non-GAAP Diluted EPS by about $1.10 for the third quarter of 2025. BioMarin’s financial results for the period are still under finalization and may vary from these preliminary estimates. Meanwhile, Bernstein SocGen Group has increased its price target for BioMarin to $95, following the Inozyme acquisition, maintaining an Outperform rating. Additionally, Cantor Fitzgerald has lowered its price target on BioMarin to $80 but continues to rate the stock as Overweight.
Oppenheimer has reiterated an Outperform rating with a $98 price target, citing the strength of BioMarin’s Voxzogo franchise. In other developments, BioMarin’s drug PALYNZIQ has shown a significant reduction in blood phenylalanine levels in adolescents with phenylketonuria, according to data from the Phase 3 PEGASUS study. The study highlighted a 49.7% decrease in mean blood Phe levels in treated adolescents compared to a 0.3% reduction with diet alone. These recent developments reflect BioMarin’s ongoing strategic moves and product efficacy in the pharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.